Education
About Us
Working with TipRanks
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
IMCR Stock Chart & Stats
$31.93
-$0.07(-0.21%)
At close: 4:00 PM EST
$31.93
-$0.07(-0.21%)
Day’s Range― - ―
52-Week Range$23.15 - $40.71
Previous CloseN/A
Volume28.13K
Average Volume (3M)459.01K
Market Cap
$1.62B
Enterprise Value$1.19B
Total Cash (Recent Filing)$864.15M
Total Debt (Recent Filing)$43.56M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 13, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding50,695,080
10 Day Avg. Volume426,817
30 Day Avg. Volume459,013
Financial Highlights & Ratios
PEG Ratio1.38
Price to Book (P/B)4.59
Price to Sales (P/S)5.87
P/FCF Ratio-156.07
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue3.20
Enterprise Value/Gross Profit3.25
Enterprise Value/Ebitda-3.68K
Forecast
1Y Price Target
$65.75Price Target Upside105.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.92
Revenue Forecast (FY)$448.32M
Bulls Say, Bears Say
Bulls Say
Clinical Trial CatalystAn on-track Phase 3 TEBE-AM program with the potential for overall survival data represents a pivotal efficacy milestone that could materially expand the therapy's eligible patient population if successful.
Commercial MomentumBroad commercial adoption of Kimmtrak across regions and expansion into community clinics is sustaining consecutive sales growth and funding ongoing development programs.
Pipeline DiversificationA diversified late-stage pipeline across oncology, infectious disease, and autoimmune indications creates multiple opportunities to add value beyond the lead product.
Bears Say
Guidance-driven Forecast AdjustmentsExpectations of slower growth have prompted analysts to model more moderate revenue expansion, which could temper upside in the stock's valuation.
Market Saturation And Moderating GrowthManagement guidance pointing to moderating revenue growth as market penetration deepens suggests top-line expansion may decelerate from earlier launch phases.
Treatment-duration Impact On New StartsLonger treatment durations reduce the frequency of new patient starts, which can constrain natural revenue growth and make future gains dependent on deeper US market share and new market entries.
Immunocore Holdings News
IMCR FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was $23.15 and its highest was $40.71 in the past 12 months.
What is Immunocore Holdings’s market cap?
Immunocore Holdings’s market cap is $1.62B.
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is May 13, 2026 which is in 67 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.232 by $0.232.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -0.26.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 50,695,080 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of $0 in its last earnings report, beating expectations of -$0.232. Following the earnings report the stock price went up 2.597%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Currently, no hedge funds are holding shares in IMCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunocore Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.75 (105.92% Upside)
$65.75 (105.92% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 357.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.55%
12-Months-Change
Fundamentals
Return on Equity
-9.59%
Trailing 12-Months
Asset Growth
5.72%
Trailing 12-Months
Company Description
Immunocore Holdings
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
IMCR Stock 12 Month Forecast
Average Price Target
$65.75
▲(105.92% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---